Boston Scientific Sees Unusually Large Options Volume (NYSE:BSX)

Boston Scientific Corporation (NYSE:BSX) saw some unusual options trading activity on Tuesday. Stock traders acquired 60,185 call options on the company. This is an increase of approximately 154% compared to the typical volume of 23,684 call options.

Wall Street Analyst Weigh In

BSX has been the subject of a number of analyst reports. Truist Financial reduced their price target on Boston Scientific from $92.00 to $90.00 and set a “buy” rating for the company in a report on Wednesday, April 15th. Raymond James Financial reissued an “outperform” rating and issued a $88.00 price objective (down from $97.00) on shares of Boston Scientific in a report on Monday, March 30th. JPMorgan Chase & Co. cut their price objective on Boston Scientific from $135.00 to $100.00 and set an “overweight” rating for the company in a research report on Thursday, February 5th. Wells Fargo & Company reduced their target price on Boston Scientific from $125.00 to $94.00 and set an “overweight” rating for the company in a research note on Thursday, February 5th. Finally, Argus raised shares of Boston Scientific to a “strong-buy” rating in a research note on Thursday, February 26th. One analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat, Boston Scientific presently has a consensus rating of “Moderate Buy” and a consensus target price of $102.59.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, CEO Michael F. Mahoney sold 160,901 shares of the company’s stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $93.49, for a total value of $15,042,634.49. Following the completion of the transaction, the chief executive officer owned 1,411,735 shares in the company, valued at approximately $131,983,105.15. This represents a 10.23% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 0.34% of the company’s stock.

Hedge Funds Weigh In On Boston Scientific

A number of institutional investors and hedge funds have recently bought and sold shares of BSX. Brighton Jones LLC grew its position in shares of Boston Scientific by 0.8% in the fourth quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock valued at $2,445,000 after purchasing an additional 226 shares in the last quarter. FWL Investment Management LLC purchased a new position in Boston Scientific during the second quarter worth approximately $26,000. Main Street Financial Solutions LLC boosted its stake in Boston Scientific by 35.3% during the second quarter. Main Street Financial Solutions LLC now owns 7,556 shares of the medical equipment provider’s stock worth $812,000 after buying an additional 1,971 shares during the last quarter. Ieq Capital LLC grew its holdings in Boston Scientific by 97.0% in the 2nd quarter. Ieq Capital LLC now owns 123,592 shares of the medical equipment provider’s stock valued at $13,275,000 after buying an additional 60,860 shares in the last quarter. Finally, HUB Investment Partners LLC grew its holdings in Boston Scientific by 56.2% in the 2nd quarter. HUB Investment Partners LLC now owns 7,102 shares of the medical equipment provider’s stock valued at $763,000 after buying an additional 2,556 shares in the last quarter. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Key Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Unusually large call-option buying: investors purchased ~60,185 call options today (about a 154% jump vs. normal), signaling speculative bullish positioning or hedging ahead of catalysts such as earnings and potential regulatory wins.
• Positive Sentiment: Analyst backing and long-term upside remain: despite recent downdraft, many firms still carry Buy/Outperform ratings and the median analyst target across recent reports sits near $100, implying material upside from current levels. Wall Street Refuses to Blink
• Neutral Sentiment: Pre-earnings positioning and scheduled Q1 report: the company reports Q1 results Wednesday (pre-market), which is driving de-risking and volatility into the print — investors are positioning for guidance and procedure trends. Q1 2026 Earnings Preview
• Neutral Sentiment: Mixed analyst tweaks: Stifel trimmed its price target (now $85) but kept a Buy rating, and Truist slightly cut its PT to $90 while remaining constructive — these are modest downward revisions but not a shift to sell consensus. Boston Scientific Stock Is Trending Today
• Negative Sentiment: Surge of securities class-action notices and filings: multiple law firms (Pomerantz, Portnoy, Faruqi, Robbins, Rosen, Bernstein Liebhard, etc.) have announced suits or investor alerts tied to a July 23, 2025–Feb 3, 2026 class period and a May 4 lead-plaintiff deadline — this increases headline/legal risk and could pressure sentiment and costs. Pomerantz Investor Alert
• Negative Sentiment: Near-term technical/valuation pressure: coverage notes and commentary report BSX near a 52-week low with YTD weakness and some analysts trimming forecasts — these factors contribute to selling momentum ahead of earnings. 52-Week Low Coverage
• Negative Sentiment: Insider selling and institutional rebalances noted in data summaries may amplify negative sentiment when combined with legal headlines and uncertain near-term procedure trends. Quiver/Market Analysis

Boston Scientific Stock Down 2.5%

Shares of BSX opened at $59.46 on Wednesday. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.08 and a current ratio of 1.62. Boston Scientific has a one year low of $59.38 and a one year high of $109.50. The stock has a market capitalization of $88.37 billion, a price-to-earnings ratio of 30.65, a PEG ratio of 0.94 and a beta of 0.78. The stock has a 50 day moving average price of $69.04 and a 200 day moving average price of $86.31.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share for the quarter, beating analysts’ consensus estimates of $0.78 by $0.02. Boston Scientific had a return on equity of 19.63% and a net margin of 14.44%.The company had revenue of $5.29 billion for the quarter, compared to analyst estimates of $5.29 billion. During the same quarter last year, the firm posted $0.70 EPS. The firm’s revenue for the quarter was up 15.9% on a year-over-year basis. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. Equities research analysts forecast that Boston Scientific will post 3.45 earnings per share for the current fiscal year.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.